Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853340 | 0.83 | APP (1.00) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL2061130 | 0.83 | APP (1.00) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL7109596 | 0.83 | APP (0.68) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL10311766 | 0.83 | APP (0.68) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL10032135 | 0.83 | APP (0.71) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL5691080 | 0.83 | APP (0.71) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL10311757 | 0.83 | APP (0.70) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL2061208 | 0.83 | APP (0.70) | APPGLAGAASNCACYP1A2 | |
| SCHEMBL2628249 | 0.81 | APP (0.94) | APPMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL1726512 | 0.81 | APP (1.00) | APPMAPTRAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812319-B9 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2003-10-08 | — | — | EP | claimed |
| EP-0812319-B1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2002-07-10 | — | — | EP | claimed |
| US-6034246-A | ANTICANCER AGENT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-03-07 | — | — | US | claimed |
| WO-1996026932-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-09-06 | — | — | WO | claimed |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-02-01 | — | — | US | disclosed |
| US-9808541-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) | 2017-11-07 | — | — | US | disclosed |
| US-20150165073-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-06-18 | — | — | US | disclosed |
| US-8911707-B2 | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-12-16 | — | — | US | disclosed |
| US-8580229-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130236394-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-09-12 | — | — | US | disclosed |
| EP-1771208-B1 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING FOR ASSESSING ANTI-AMYLOID THERAPIES | UNIV PITTSBURGH (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8404213-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130045164-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-8343457-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120177572-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-07-12 | — | — | US | disclosed |
| US-20110257407-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2011-10-20 | — | — | US | disclosed |
| EP-0812319-B9 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2003-10-08 | — | — | EP | disclosed |
| EP-0812319-B1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2002-07-10 | — | — | EP | disclosed |
| US-6034246-A | ANTICANCER AGENT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| WO-1996026932-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236394-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885MAPT 3/4885RAB9A 3305/4885 |
| US-20120177572-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | TTR, APP, SAAL1 | APP 2/4885MAPT 14/4885RAB9A 3270/4885 |
| US-20130045164-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | TTR, APP, SAAL1 | APP 2/4885MAPT 14/4885RAB9A 3270/4885 |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885MAPT 3/4885RAB9A 3340/4885 |
| US-20150165073-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885MAPT 3/4885RAB9A 3340/4885 |
| US-20110257407-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885MAPT 3/4885RAB9A 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.